Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up.

[1]  H. Nelson,et al.  Hormone Replacement Therapy and Risk of Venous Thromboembolism , 2002 .

[2]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[3]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[4]  D. Herrington,et al.  The Heart and Estrogen/Progestin Replacement Study , 1999, Drugs & aging.

[5]  C. Björkelund,et al.  Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden , 1999, BMJ.

[6]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[7]  P. Ridker,et al.  Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. , 1998, Circulation.

[8]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[9]  E. Baracat,et al.  Effect of estrogen‐progestin hormonal replacement therapy on plasma antithrombin III of postmenopausal women , 1998, Acta obstetricia et gynecologica Scandinavica.

[10]  MartineAiach,et al.  Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women , 1997 .

[11]  M. Aiach,et al.  Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[12]  C. Furberg,et al.  Venous thromboembolic events associated with hormone replacement therapy. , 1997, JAMA.

[13]  Coumadin Aspirin Reinfarction Study Investigators.  Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction , 1997, The Lancet.

[14]  M. Marmot,et al.  Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study , 1997, The Lancet.

[15]  B. Christie.  Inquiry calls for doctors to be tested regularly for alcohol , 1997 .

[16]  R. Tomlinson.  China bans smoking on trains and buses , 1997 .

[17]  J. Castellsagué,et al.  Hormone replacement therapy and risk of venous thromboembolism: population based case-control study , 1997, BMJ.

[18]  C. Kessler,et al.  Estrogen replacement therapy and coagulation: Relationship to lipid and lipoprotein changes , 1997, Obstetrics and gynecology.

[19]  R. Califf,et al.  Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. , 1996, Journal of the American College of Cardiology.

[20]  J. Carson,et al.  Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.

[21]  J. Manson,et al.  Prospective study of exogenous hormones and risk of pulmonary embolism in women , 1996, The Lancet.

[22]  K. Newton,et al.  Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens , 1996, The Lancet.

[23]  P. Scarabin,et al.  Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[24]  J. Manson,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[25]  K. Matthews,et al.  Prior to use of estrogen replacement therapy, are users healthier than nonusers? , 1996, American journal of epidemiology.

[26]  M. Tortajada,et al.  The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. , 1995, American journal of obstetrics and gynecology.

[27]  Susan R. Johnson,et al.  Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .

[28]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[29]  S. Shapiro,et al.  Reproductive factors and risk of myocardial infarction. , 1992, American journal of epidemiology.

[30]  M. Napoli,et al.  Postmenopausal Estrogen and Prevention Bias , 1992, Annals of Internal Medicine.

[31]  G A Colditz,et al.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. , 2004, Preventive medicine.

[32]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[33]  D. Mirvis,et al.  Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. , 1990, Archives of internal medicine.

[34]  P. Wilson,et al.  Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. , 1985, The New England journal of medicine.

[35]  A. Paganini-Hill,et al.  Estrogen Replacement Therapy and Coronary Heart Disease , 1983 .

[36]  B. Barnes.  The Coronary Drug Project , 1972 .

[37]  The Coronary Drug Project. Initial findings leading to modifications of its research protocol. , 1970, JAMA.

[38]  J. Stamler,et al.  Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. , 1963, JAMA.